Gelesis picks up $64.3 mln

Gelesis, a biotechnology company focused on treating chronic diseases related to the gastrointestinal tract, has secured $64.3 million in funding.

Gelesis, a biotechnology company focused on treating chronic diseases related to the gastrointestinal tract, has secured $64.3 million in funding. Vitruvian Partners led the round.

Source: Press Release